VALIANT LABORATORIES
|
|
BOM : 543998     NSE : VALIANTLAB     | |
LT :  
    Long Term Analysis
Fundamentals : Bad
Valuation : Bad [Stock is Expensive] Debt : High |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Downward
Price Momentum : Mild Upward Pledged Shares : NA |
May 03,2024 |
Price(EOD): ₹ 152.95
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 665.33 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
VALIANT LABORATORIES | -2.6% | 0.4% | NA |
SUN PHARMACEUTICAL INDUSTRIES | 0.3% | -7.5% | 53.9% |
CIPLA | 1.1% | -4.8% | 56.4% |
DR REDDYS LABORATORIES | 1.6% | 1.6% | 27.6% |
ZYDUS LIFESCIENCES | 5.2% | -0.2% | 90.1% |
DIVIS LABORATORIES | -1.9% | 10.7% | 21.4% |
MANKIND PHARMA | -2.3% | 0.1% | NA |
TORRENT PHARMACEUTICALS | 1.6% | 2% | 61.8% |
LUPIN | 2.4% | 2% | 132.5% |
FUNDAMENTAL ANALYSIS OF VALIANT LABORATORIES
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF VALIANT LABORATORIES
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
48.88
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 13.60 Cr
[Latest Qtr - Dec2023 - Consolidated Results ] 6.61
P/B Calculated based on Book Value of Rs 100.49 Cr
[Latest Year - Mar2023 - Consolidated Results ] 2.57
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 258.79 Cr
[Latest Qtr - Dec2023 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
15668% 44885% - |
SHARE PRICE MOMENTUM OF VALIANT LABORATORIES
VALIANT LABORATORIES vs SENSEX
DEBT OF VALIANT LABORATORIES
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2023 2022 2021 Avg_3yrs |
0.59 0.85 - 0.48 |
0.59 - - 0.2 |
[Last Annual Data : Mar2023]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF VALIANT LABORATORIES
Pledged Promoter Shares |
NA | |
---|---|---|
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF VALIANT LABORATORIES
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
-31.96% -355.05% -574.15% -541.18% |
NA -522.16% NA NA |
QtrlyTrend |
-5 | |
Latest Qtr: Dec2023 | ||
Quarterly Result Analysis → |
VALIANT LABORATORIES related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE IPO | 0.7% | 9.2% | 77.2% |
You may also like the below Video Courses
FAQ about VALIANT LABORATORIES
Is VALIANT LABORATORIES good for long term investment?
As on May 03,2024, the Fundamentals of VALIANT LABORATORIES look Poor and hence it may not be good for long term investment ! See Financial Performance of VALIANT LABORATORIES . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is VALIANT LABORATORIES UnderValued or OverValued?
As on May 03,2024, VALIANT LABORATORIES is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of VALIANT LABORATORIES ?
As on May 03,2024, the Intrinsic Value of VALIANT LABORATORIES is Rs. 0.65 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 0.97
Fair Value [Median EV / Sales Model] : Rs. 0.34
Fair Value [Median Price / Sales Model] : Rs. 0.00
Estimated Median Fair Value of VALIANT LABORATORIES : Rs. 0.65
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.